Literature DB >> 32961340

Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda.

Amit G Singal1, Anna S Lok2, Ziding Feng3, Fasiha Kanwal4, Neehar D Parikh2.   

Abstract

Hepatocellular carcinoma (HCC) continues to have a dismal prognosis, with 5-year survival below 20%. This poor prognosis can be in part attributed to failures along the cancer screening process continuum such as underuse of screening in at risk patients and appropriate treatments for patients with HCC. Better understanding these process failures, and how they compare to those seen in other cancer types, can help inform potential intervention targets and strategies to reduce HCC-related mortality. Herein, we outline a conceptual model with several discrete steps in the HCC screening process continuum including risk assessment, screening initiation, follow-up of screening results, diagnostic evaluation, and treatment evaluation. The conceptual model illustrates how each step in the screening process is prone to delays or failure, resulting in worse outcomes such as late stage diagnosis or poor survival, and how factors at the patient, provider, and health care system levels can contribute to these failures. We compare cancer screening processes for HCC with those employed in breast and colorectal cancer screening to identify opportunities for improvement. The Translational Liver Cancer consortium was recently established by the National Cancer Institute with the goal of improving early detection of HCC. Studies designed to address failures in the HCC screening process continuum will help accomplish this goal.
Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diagnosis; Liver Cancer; Screening Process; Surveillance

Mesh:

Year:  2020        PMID: 32961340      PMCID: PMC8287785          DOI: 10.1016/j.cgh.2020.09.036

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  56 in total

1.  Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C.

Authors:  George N Ioannou; Pamela K Green; Lauren A Beste; Elijah J Mun; Kathleen F Kerr; Kristin Berry
Journal:  J Hepatol       Date:  2018-08-21       Impact factor: 25.083

2.  Evaluating Screening Participation, Follow-up, and Outcomes for Breast, Cervical, and Colorectal Cancer in the PROSPR Consortium.

Authors:  William E Barlow; Elisabeth F Beaber; Berta M Geller; Aruna Kamineni; Yingye Zheng; Jennifer S Haas; Chun R Chao; Carolyn M Rutter; Ann G Zauber; Brian L Sprague; Ethan A Halm; Donald L Weaver; Jessica Chubak; V Paul Doria-Rose; Sarah Kobrin; Tracy Onega; Virginia P Quinn; Marilyn M Schapira; Anna N A Tosteson; Douglas A Corley; Celette Sugg Skinner; Mitchell D Schnall; Katrina Armstrong; Cosette M Wheeler; Michael J Silverberg; Bijal A Balasubramanian; Chyke A Doubeni; Dale McLerran; Jasmin A Tiro
Journal:  J Natl Cancer Inst       Date:  2020-03-01       Impact factor: 13.506

3.  Development of Quality Measures in Cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.

Authors:  Fasiha Kanwal; Elliot B Tapper; Chanda Ho; Sumeet K Asrani; Nadia Ovchinsky; John Poterucha; Avegail Flores; Victor Ankoma-Sey; Bruce Luxon; Michael Volk
Journal:  Hepatology       Date:  2019-03-12       Impact factor: 17.425

4.  Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma.

Authors:  Ju Dong Yang; W Ray Kim; Ritika Coelho; Teresa A Mettler; Joanne T Benson; Schuyler O Sanderson; Terry M Therneau; Bohyun Kim; Lewis R Roberts
Journal:  Clin Gastroenterol Hepatol       Date:  2010-09-08       Impact factor: 11.382

5.  Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease.

Authors:  Sahil Mittal; Hashem B El-Serag; Yvonne H Sada; Fasiha Kanwal; Zhigang Duan; Sarah Temple; Sarah B May; Jennifer R Kramer; Peter A Richardson; Jessica A Davila
Journal:  Clin Gastroenterol Hepatol       Date:  2015-07-18       Impact factor: 11.382

6.  Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.

Authors:  Zobair Younossi; Maria Stepanova; Janus P Ong; Ira M Jacobson; Elisabetta Bugianesi; Ajay Duseja; Yuichiro Eguchi; Vincent W Wong; Francesco Negro; Yusuf Yilmaz; Manuel Romero-Gomez; Jacob George; Aijaz Ahmed; Robert Wong; Issah Younossi; Mariam Ziayee; Arian Afendy
Journal:  Clin Gastroenterol Hepatol       Date:  2018-06-14       Impact factor: 11.382

7.  Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease.

Authors:  Fasiha Kanwal; Jennifer R Kramer; Srikar Mapakshi; Yamini Natarajan; Maneerat Chayanupatkul; Peter A Richardson; Liang Li; Roxanne Desiderio; Aaron P Thrift; Steven M Asch; Jinna Chu; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2018-08-23       Impact factor: 22.682

8.  Failure rates in the hepatocellular carcinoma surveillance process.

Authors:  Amit G Singal; Adam C Yopp; Samir Gupta; Celette Sugg Skinner; Ethan A Halm; Eucharia Okolo; Mahendra Nehra; William M Lee; Jorge A Marrero; Jasmin A Tiro
Journal:  Cancer Prev Res (Phila)       Date:  2012-07-30

9.  Accuracy of the Liver Imaging Reporting and Data System in Computed Tomography and Magnetic Resonance Image Analysis of Hepatocellular Carcinoma or Overall Malignancy-A Systematic Review.

Authors:  Christian B van der Pol; Christopher S Lim; Claude B Sirlin; Trevor A McGrath; Jean-Paul Salameh; Mustafa R Bashir; An Tang; Amit G Singal; Andreu F Costa; Kathryn Fowler; Matthew D F McInnes
Journal:  Gastroenterology       Date:  2018-11-13       Impact factor: 22.682

10.  Association Between Time to Colonoscopy After a Positive Fecal Test Result and Risk of Colorectal Cancer and Cancer Stage at Diagnosis.

Authors:  Douglas A Corley; Christopher D Jensen; Virginia P Quinn; Chyke A Doubeni; Ann G Zauber; Jeffrey K Lee; Joanne E Schottinger; Amy R Marks; Wei K Zhao; Nirupa R Ghai; Alexander T Lee; Richard Contreras; Charles P Quesenberry; Bruce H Fireman; Theodore R Levin
Journal:  JAMA       Date:  2017-04-25       Impact factor: 56.272

View more
  18 in total

1.  Clinical Course and Outcomes of Patients with Nonalcoholic Fatty Liver Disease-Related Hepatocellular Cancer (NAFLD-HCC).

Authors:  Jinna Chu; George Cholankeril; Xian Yu; Abbas Rana; Yamini Natarajan; Hashem B El-Serag; Jennifer Kramer; Fasiha Kanwal
Journal:  Dig Dis Sci       Date:  2022-06-27       Impact factor: 3.487

2.  Regulation of Gamma-Aminobutyric Acid Transaminase Expression and Its Clinical Significance in Hepatocellular Carcinoma.

Authors:  Xiaoqiang Gao; Xiaodong Jia; Moyan Xu; Jiao Xiang; Jin Lei; Yinyin Li; Yinying Lu; Shi Zuo
Journal:  Front Oncol       Date:  2022-06-24       Impact factor: 5.738

3.  Depleting circ_0088364 restrained cell growth and motility of human hepatocellular carcinoma via circ_0088364-miR-1270-COL4A1 ceRNA pathway.

Authors:  Kai Sun; Haochen Wang; Dongyuan Zhang; Yupeng Li; Lei Ren
Journal:  Cell Cycle       Date:  2021-12-24       Impact factor: 4.534

Review 4.  Rational HCC screening approaches for patients with NAFLD.

Authors:  Amit G Singal; Hashem B El-Serag
Journal:  J Hepatol       Date:  2021-09-09       Impact factor: 25.083

5.  Novel Application of Predictive Modeling: A Tailored Approach to Promoting HCC Surveillance in Patients With Cirrhosis.

Authors:  Amit G Singal; Yixing Chen; Shrihari Sridhar; Vikas Mittal; Hannah Fullington; Muzeeb Shaik; Akbar K Waljee; Jasmin Tiro
Journal:  Clin Gastroenterol Hepatol       Date:  2021-03-02       Impact factor: 13.576

6.  A multi-analyte cell-free DNA-based blood test for early detection of hepatocellular carcinoma.

Authors:  Nan Lin; Yongping Lin; Jianfeng Xu; Dan Liu; Diange Li; Hongyu Meng; Maxime A Gallant; Naoto Kubota; Dhruvajyoti Roy; Jason S Li; Emmanuel C Gorospe; Morris Sherman; Robert G Gish; Ghassan K Abou-Alfa; Mindie H Nguyen; David J Taggart; Richard A Van Etten; Yujin Hoshida; Wei Li
Journal:  Hepatol Commun       Date:  2022-03-03

7.  Racial and Ethnic Disparities in Survival Among Patients With Hepatocellular Carcinoma in the United States: A Systematic Review and Meta-Analysis.

Authors:  Nicole E Rich; Christian Carr; Adam C Yopp; Jorge A Marrero; Amit G Singal
Journal:  Clin Gastroenterol Hepatol       Date:  2020-12-30       Impact factor: 11.382

8.  External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.

Authors:  Thierry Poynard; Jean Marc Lacombe; Olivier Deckmyn; Valentina Peta; Sepideh Akhavan; Victor de Ledinghen; Fabien Zoulim; Didier Samuel; Philippe Mathurin; Vlad Ratziu; Dominique Thabut; Chantal Housset; Hélène Fontaine; Stanislas Pol; Fabrice Carrat
Journal:  JHEP Rep       Date:  2021-04-24

9.  NAFLD and HCC: Time to Bridge the Gap.

Authors:  George Cholankeril; Fasiha Kanwal
Journal:  Hepatology       Date:  2021-08-30       Impact factor: 17.298

10.  Patient Preferences for Hepatocellular Carcinoma Surveillance Parameters.

Authors:  Sean A Woolen; Amit G Singal; Matthew S Davenport; Jonathan P Troost; Shokoufeh Khalatbari; Sukul Mittal; Sehar Siddiqui; Austin Fobar; Jason Morris; Mobolaji Odewole; Elliot B Tapper; Anjana Pillai; Neehar D Parikh
Journal:  Clin Gastroenterol Hepatol       Date:  2021-02-19       Impact factor: 13.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.